<DOC>
	<DOC>NCT00696748</DOC>
	<brief_summary>The objective of the study is to assess the effect of the testosterone therapy on the body composition, lipid and glucose metabolism, inflammatory markers in patients with metabolic syndrome and hypogonadism.</brief_summary>
	<brief_title>The Effect of IM Testosterone Undecanoate on Biochemical and Anthropometric Characteristics of Metabolic Syndrome in Hypogonadal Men</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>A signed informed consent to participate in the study Men aged 35 to 70 with testosterone levels below 12 nmol/L or free testosterone below 225 pmol/L Presence of the metabolic syndrome according to the IDF definition Patients under 35 or above 70 years. Participation in any clinical study within 30 days before the first injection of the drug Simultaneous participation in another clinical study Incapable subjects as well as prisoners Suspicion of a serious organic or mental disease according to medical history and/or clinical examination Prostate cancer, breast cancer or suspicion thereof Presence or history of hepatic tumors Acute or chronic hepatic disease Presence of renal diseases with renal failure Changes in biochemical or hematological laboratory values in spite of lack of clinical manifestations, in the investigator's opinion Suspected lack of the patient's compliance Hypersensitivity to the active substance</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>metabolic syndrome</keyword>
	<keyword>hypogonadism</keyword>
	<keyword>testosterone undecanoate</keyword>
</DOC>